메뉴 건너뛰기




Volumn 22, Issue 2, 2011, Pages 355-361

Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study

Author keywords

5 fluorouracil; Orotate phosphoribosyltransferase; Polymorphism; Tegafur uracil; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOCHROME P450 2A6; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; METHYLENETETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; METHYLENETETRAHYDROFOLIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; UFT; UNCLASSIFIED DRUG;

EID: 79251549824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq358     Document Type: Article
Times cited : (27)

References (43)
  • 1
    • 0032874395 scopus 로고    scopus 로고
    • The oral fluoropyrimidines in cancer chemotherapy
    • Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999; 5: 2289-2296.
    • (1999) Clin Cancer Res , vol.5 , pp. 2289-2296
    • Lamont, E.B.1    Schilsky, R.L.2
  • 2
    • 13744251436 scopus 로고    scopus 로고
    • Systemic therapy for colorectal cancer
    • Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
    • (2005) N Engl J Med , vol.352 , pp. 476-487
    • Meyerhardt, J.A.1    Mayer, R.J.2
  • 3
    • 2942648695 scopus 로고    scopus 로고
    • Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy
    • Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232.
    • (2004) J Clin Oncol , vol.22 , pp. 2214-2232
    • Rich, T.A.1    Shepard, R.C.2    Mosley, S.T.3
  • 4
    • 0018757734 scopus 로고
    • Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
    • Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
    • (1979) Gann , vol.70 , pp. 209-214
    • Fujii, S.1    Kitano, S.2    Ikenaka, K.3    Shirasaka, T.4
  • 5
    • 33646443236 scopus 로고    scopus 로고
    • Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    • Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
    • (2006) J Clin Oncol , vol.24 , pp. 2059-2064
    • Lembersky, B.C.1    Wieand, H.S.2    Petrelli, N.J.3
  • 6
    • 33846990133 scopus 로고    scopus 로고
    • Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06
    • Kopec JA, Yothers G, Ganz PA et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25: 424-430.
    • (2007) J Clin Oncol , vol.25 , pp. 424-430
    • Kopec, J.A.1    Yothers, G.2    Ganz, P.A.3
  • 7
    • 0035138840 scopus 로고    scopus 로고
    • Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
    • Nakajima M, Kwon JT, Tanaka N et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-78.
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 72-78
    • Nakajima, M.1    Kwon, J.T.2    Tanaka, N.3
  • 8
    • 21044434731 scopus 로고    scopus 로고
    • Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
    • Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005; 11: 3778-3783.
    • (2005) Clin Cancer Res , vol.11 , pp. 3778-3783
    • Kawakami, K.1    Graziano, F.2    Watanabe, G.3
  • 9
    • 0642286407 scopus 로고    scopus 로고
    • Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis
    • Kumagai K, Hiyama K, Oyama T et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593-600.
    • (2003) Int J Mol Med , vol.11 , pp. 593-600
    • Kumagai, K.1    Hiyama, K.2    Oyama, T.3
  • 10
    • 0032713815 scopus 로고    scopus 로고
    • Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations
    • Harmon DL, Shields DC, Woodside JV et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17: 298-309.
    • (1999) Genet Epidemiol , vol.17 , pp. 298-309
    • Harmon, D.L.1    Shields, D.C.2    Woodside, J.V.3
  • 11
    • 0033805360 scopus 로고    scopus 로고
    • A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia
    • Chango A, Emery-Fillon N, de Courcy GP et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310-315.
    • (2000) Mol Genet Metab , vol.70 , pp. 310-315
    • Chango, A.1    Emery-Fillon, N.2    de Courcy, G.P.3
  • 12
    • 2942527225 scopus 로고    scopus 로고
    • UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
    • Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 501-515
    • Sai, K.1    Saeki, M.2    Saito, Y.3
  • 13
    • 13544260840 scopus 로고    scopus 로고
    • CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians
    • Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J 2005; 5: 42-48.
    • (2005) Pharmacogenomics J , vol.5 , pp. 42-48
    • Vasconcelos, G.M.1    Struchiner, C.J.2    Suarez-Kurtz, G.3
  • 14
    • 0036016314 scopus 로고    scopus 로고
    • A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur
    • Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299-306.
    • (2002) Pharmacogenetics , vol.12 , pp. 299-306
    • Daigo, S.1    Takahashi, Y.2    Fujieda, M.3
  • 15
    • 0036299144 scopus 로고    scopus 로고
    • An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
    • Xu C, Rao YS, Xu B et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318-324.
    • (2002) Biochem Biophys Res Commun , vol.290 , pp. 318-324
    • Xu, C.1    Rao, Y.S.2    Xu, B.3
  • 16
    • 33746102909 scopus 로고    scopus 로고
    • Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen
    • Ichikawa W, Takahashi T, Suto K et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-3934.
    • (2006) Clin Cancer Res , vol.12 , pp. 3928-3934
    • Ichikawa, W.1    Takahashi, T.2    Suto, K.3
  • 17
    • 0018744377 scopus 로고
    • Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine
    • Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979; 39: 2406-2413.
    • (1979) Cancer Res , vol.39 , pp. 2406-2413
    • Houghton, J.A.1    Houghton, P.J.2    Wooten, R.S.3
  • 18
    • 0035750549 scopus 로고    scopus 로고
    • Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
    • Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
    • (2001) Pharmacogenomics J , vol.1 , pp. 65-70
    • Pullarkat, S.T.1    Stoehlmacher, J.2    Ghaderi, V.3
  • 19
    • 0037990003 scopus 로고    scopus 로고
    • Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
    • Cohen V, Panet-Raymond V, Sabbaghian N et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
    • (2003) Clin Cancer Res , vol.9 , pp. 1611-1615
    • Cohen, V.1    Panet-Raymond, V.2    Sabbaghian, N.3
  • 20
    • 14944380124 scopus 로고    scopus 로고
    • Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
    • Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
    • (2005) J Clin Oncol , vol.23 , pp. 1365-1369
    • Jakobsen, A.1    Nielsen, J.N.2    Gyldenkerne, N.3    Lindeberg, J.4
  • 21
    • 4444339951 scopus 로고    scopus 로고
    • Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
    • Lecomte T, Ferraz JM, Zinzindohoue F et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
    • (2004) Clin Cancer Res , vol.10 , pp. 5880-5888
    • Lecomte, T.1    Ferraz, J.M.2    Zinzindohoue, F.3
  • 22
    • 38949175429 scopus 로고    scopus 로고
    • Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients
    • Sharma R, Hoskins JM, Rivory LP et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14: 817-825.
    • (2008) Clin Cancer Res , vol.14 , pp. 817-825
    • Sharma, R.1    Hoskins, J.M.2    Rivory, L.P.3
  • 23
    • 0142150084 scopus 로고    scopus 로고
    • Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer
    • Chen J, Hunter DJ, Stampfer MJ et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958-962.
    • (2003) Cancer Epidemiol Biomarkers Prev , vol.12 , pp. 958-962
    • Chen, J.1    Hunter, D.J.2    Stampfer, M.J.3
  • 24
    • 0027945196 scopus 로고
    • Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
    • Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239-2242.
    • (1994) J Clin Oncol , vol.12 , pp. 2239-2242
    • Diasio, R.B.1    Lu, Z.2
  • 25
    • 0023902287 scopus 로고
    • Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
    • Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
    • (1988) J Clin Invest , vol.81 , pp. 47-51
    • Diasio, R.B.1    Beavers, T.L.2    Carpenter, J.T.3
  • 26
    • 0034901306 scopus 로고    scopus 로고
    • Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency
    • van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
    • (2001) Clin Cancer Res , vol.7 , pp. 1149-1153
    • van Kuilenburg, A.B.1    Muller, E.W.2    Haasjes, J.3
  • 27
    • 0035074119 scopus 로고    scopus 로고
    • Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil
    • Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001; 92: 337-342.
    • (2001) Jpn J Cancer Res , vol.92 , pp. 337-342
    • Yamaguchi, K.1    Arai, Y.2    Kanda, Y.3    Akagi, K.4
  • 28
    • 0034050905 scopus 로고    scopus 로고
    • Known variant DPYD alleles do not explain DPD deficiency in cancer patients
    • Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-223.
    • (2000) Pharmacogenetics , vol.10 , pp. 217-223
    • Collie-Duguid, E.S.1    Etienne, M.C.2    Milano, G.3    McLeod, H.L.4
  • 29
    • 7344249042 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
    • Ridge SA, Sludden J, Brown O et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46: 151-156.
    • (1998) Br J Clin Pharmacol , vol.46 , pp. 151-156
    • Ridge, S.A.1    Sludden, J.2    Brown, O.3
  • 30
    • 36249014288 scopus 로고    scopus 로고
    • DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients
    • Zhang H, Li YM, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-258.
    • (2007) Med Oncol , vol.24 , pp. 251-258
    • Zhang, H.1    Li, Y.M.2    Jin, X.3
  • 31
    • 0022656553 scopus 로고
    • Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes
    • Peters GJ, Laurensse E, Leyva A et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20-28.
    • (1986) Cancer Res , vol.46 , pp. 20-28
    • Peters, G.J.1    Laurensse, E.2    Leyva, A.3
  • 32
    • 43749114271 scopus 로고    scopus 로고
    • Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group
    • Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
    • (2008) J Clin Oncol , vol.26 , pp. 2131-2138
    • Schwab, M.1    Zanger, U.M.2    Marx, C.3
  • 33
    • 47849131155 scopus 로고    scopus 로고
    • The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer
    • Capitain O, Boisdron-Celle M, Poirier AL et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8: 256-267.
    • (2008) Pharmacogenomics J , vol.8 , pp. 256-267
    • Capitain, O.1    Boisdron-Celle, M.2    Poirier, A.L.3
  • 34
    • 0034904708 scopus 로고    scopus 로고
    • The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations
    • Gaughan DJ, Kluijtmans LA, Barbaux S et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451-456.
    • (2001) Atherosclerosis , vol.157 , pp. 451-456
    • Gaughan, D.J.1    Kluijtmans, L.A.2    Barbaux, S.3
  • 35
    • 0036562507 scopus 로고    scopus 로고
    • Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy
    • Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-552.
    • (2002) Mol Cancer Ther , vol.1 , pp. 545-552
    • Niyikiza, C.1    Baker, S.D.2    Seitz, D.E.3
  • 36
    • 0021223573 scopus 로고
    • Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil
    • Kawata S, Minami Y, Tarui S et al. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. Jpn J Pharmacol 1984; 36: 43-49.
    • (1984) Jpn J Pharmacol , vol.36 , pp. 43-49
    • Kawata, S.1    Minami, Y.2    Tarui, S.3
  • 37
    • 34250202527 scopus 로고    scopus 로고
    • Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28
    • Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17: 497-504.
    • (2007) Pharmacogenet Genomics , vol.17 , pp. 497-504
    • Minami, H.1    Sai, K.2    Saeki, M.3
  • 38
    • 39149141390 scopus 로고    scopus 로고
    • Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients
    • Sai K, Saito Y, Sakamoto H et al. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008; 261: 165-171.
    • (2008) Cancer Lett , vol.261 , pp. 165-171
    • Sai, K.1    Saito, Y.2    Sakamoto, H.3
  • 39
    • 33748925080 scopus 로고    scopus 로고
    • Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
    • Araki K, Fujita K, Ando Y et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-1259.
    • (2006) Cancer Sci , vol.97 , pp. 1255-1259
    • Araki, K.1    Fujita, K.2    Ando, Y.3
  • 40
    • 10744221779 scopus 로고    scopus 로고
    • A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia
    • Danoff TM, Campbell DA, McCarthy LC et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4: 49-53.
    • (2004) Pharmacogenomics J , vol.4 , pp. 49-53
    • Danoff, T.M.1    Campbell, D.A.2    McCarthy, L.C.3
  • 41
    • 0028867826 scopus 로고
    • The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
    • Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
    • (1995) N Engl J Med , vol.333 , pp. 1171-1175
    • Bosma, P.J.1    Chowdhury, J.R.2    Bakker, C.3
  • 42
    • 0028904620 scopus 로고
    • Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
    • Aono S, Adachi Y, Uyama E et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345: 958-959.
    • (1995) Lancet , vol.345 , pp. 958-959
    • Aono, S.1    Adachi, Y.2    Uyama, E.3
  • 43
    • 0021822511 scopus 로고
    • Pharmacology of mitoxantrone: mode of action and pharmacokinetics
    • Alberts DS, Peng YM, Bowden GT et al. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-107.
    • (1985) Invest New Drugs , vol.3 , pp. 101-107
    • Alberts, D.S.1    Peng, Y.M.2    Bowden, G.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.